Handbook of Pharmaceutical Manufacturing Formulations, Third Edition
Handbook of Pharmaceutical Manufacturing Formulations, Third Edition
Volume Three, Liquid Products
Niazi, Sarfaraz K.
Taylor & Francis Ltd
11/2019
420
Dura
Inglês
9781138103221
15 a 20 dias
1302
Manufacturing Considerations in Liquid Formulations
Oral Solutions and Suspensions
The FDA Drug Product Surveillance Program
Changes to Approved NDAs and aNDAs
Formulation Considerations of Liquid Products
Container Closure Systems
Material for Containers
Stability Testing of New Drug Substances and Products
Stability Testing: Photostability Testing of New Drug Substances and Products
Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
Evaluation of Stability Data
Stability Data Package for Registration Applications in Climatic Zones III and IV
EU Guidelines to Good Manufacturing Practice: Medicinal Products for Human and Veterinary Use
Impurities: Guideline for Residual Solvents
Electronic Records and Signatures (CFR 21 Part 11 Compliance)
Product-Specific Bioequivalence Testing Protocols
Formulation Considerations
Pediatric Pharmaceutical EU Legislation
Pediatric Formulations
SOP and Specification to Establish Electronic Submission to Regulatory Agencies
Part II: Manufacturing Formulations
Part III: Commercial Pharmaceutical Products
Manufacturing Considerations in Liquid Formulations
Oral Solutions and Suspensions
The FDA Drug Product Surveillance Program
Changes to Approved NDAs and aNDAs
Formulation Considerations of Liquid Products
Container Closure Systems
Material for Containers
Stability Testing of New Drug Substances and Products
Stability Testing: Photostability Testing of New Drug Substances and Products
Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
Evaluation of Stability Data
Stability Data Package for Registration Applications in Climatic Zones III and IV
EU Guidelines to Good Manufacturing Practice: Medicinal Products for Human and Veterinary Use
Impurities: Guideline for Residual Solvents
Electronic Records and Signatures (CFR 21 Part 11 Compliance)
Product-Specific Bioequivalence Testing Protocols
Formulation Considerations
Pediatric Pharmaceutical EU Legislation
Pediatric Formulations
SOP and Specification to Establish Electronic Submission to Regulatory Agencies
Part II: Manufacturing Formulations
Part III: Commercial Pharmaceutical Products